Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire December 13, 2023

BioSyent Announces the Availability of Gelclair® in Canada

GlobeNewswire November 20, 2023

BioSyent Releases Q3 and YTD 2023 Financial Results

GlobeNewswire November 16, 2023

BioSyent Declares Fourth Quarter 2023 Dividend

GlobeNewswire November 15, 2023

BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

GlobeNewswire November 9, 2023

BioSyent Launches "menopauseinformation.ca" on World Menopause Day

GlobeNewswire October 18, 2023

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire August 23, 2023

BioSyent Releases Q2 and H1 2023 Financial Results

GlobeNewswire August 22, 2023

BioSyent Declares Third Quarter 2023 Dividend

GlobeNewswire August 22, 2023

BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023

GlobeNewswire August 15, 2023

BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

GlobeNewswire August 8, 2023

BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer

GlobeNewswire July 6, 2023

BioSyent Announces Long-term Extension of Cathejell® Agreement

GlobeNewswire June 20, 2023

BioSyent Announces Approval of New Product

GlobeNewswire May 31, 2023

BioSyent reports Q1 2023 financial results

Shoran Devi May 26, 2023

BioSyent Releases Financial Results for Q1 2023

GlobeNewswire May 26, 2023

BioSyent Declares Second Quarter 2023 Dividend

GlobeNewswire May 25, 2023

BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023

GlobeNewswire May 18, 2023

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!

GlobeNewswire May 2, 2023

BioSyent to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 18, 2023